Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment inflated during primary HIV-1 infection

Clinical Infectious Diseases

Volumn 32, Issue 7, 2001, Pages 1095-1099

  Enting, Roelien H ^a,b   Prins, Jan M ^c   Jurriaans, Suzanne ^d   Brinkman, Kees ^c   Portegies, Peter ^c   Lange, Joep M A ^c  

^a Daniel den Hoed Cancer Center/Academic Hospital Rotterdam ^*

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BETA 2 MICROGLOBULIN; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME IMMUNOASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BETA 2-MICROGLOBULIN; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; RNA, VIRAL; VIRAL LOAD;

EID: 0035310988     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319602     Document Type: Article

References (26)

1. Diagnostic value of specific IgM antibodies in primary HIV infection
2. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: Is the diagnosis too restrictive?
3. Primary human T-lymphotropic virus type III infection
4. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection
5. In subjects with primary HIV-1 infection, high levels of HIV RNA are present in oral fluid, genital secretions, peripheral blood, and CNS and are rapidly reduced with combination antiretroviral therapy
6. Long-term evaluation of triple nucleoside therapy administered from primary HIV-1 infection
7. Measuring the "viral load" in cerebrospinal fluid in HIV infection: Window into brain infection?
8. Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy
9. Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: Support for the hypothesis of local virus replication
10. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection
11. Cerebrospinal fluid viral load in HIV-1 infected patients without antiretroviral treatment
12. Cerebrospinal fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
13. Cerebrospinal fluid mononuclear cell counts influence CSF HIV-1 RNA levels
14. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage
15. Cerebrospinal fluid HIV-1 RNA levels: Correlation with HIV encephalitis
16. Cerebrospinal fluid HIV type 1 RNA levels are elevated in neurocognitively impaired individuals with AIDS
17. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
18. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources
19. Markers of immune stimulation in the cerebrospinal fluid during HIV infection: A longitudinal study
20. 2-microglobulin and neopterin
21. Elevated neopterin and beta-2 microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection
22. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia
23. - T cell responses associated with control of viremia
24. Plasma and cerebrospinal fluid HIV-RNA and drug levels after 48 weeks of follow up of patients treated with AZT/3TC or d4T/3TC with sequential addition of indinavir
25. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples
26. Slower decline of plasma HIV-RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection